ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1754

Novel and Unique Rheumatoid Factors Cross-React with Viral Epitopes in COVID-19

Maya Amjadi1, Maxwell Parker2, Zihao Zheng1, Alex Robbins1, Michael Denny1, Sara McCoy3, Irene Ong1 and Miriam Shelef1, 1University of Wisconsin, Madison, WI, 2University of Wisconsin-Madison, Madison, WI, 3University of Wisconsin School of Medicine and Public Health, Middleton, WI

Meeting: ACR Convergence 2023

Keywords: COVID-19, rheumatoid arthritis, Rheumatoid Factor

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1734–1775) RA – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid factors (RFs), polyreactive antibodies canonically known to bind two conformational epitopes of IgG, are a hallmark of rheumatoid arthritis but also can arise in other inflammatory conditions and infections. In turn, infections, such as respiratory infections, correlate with rheumatoid arthritis development, but the mechanisms are unclear. Recently, RF reactivity in rheumatoid arthritis, and not in other autoimmune diseases, was found to include citrullinated and homocitrullinated IgG epitopes as well as thousands of citrullinated and homocitrullinated antigens targeted by anti-citrullinated protein antibodies. Specific epitopes recognized by infection-induced RFs remain undefined. The purpose of this study was to evaluate the reactivity of RFs induced in a primary immune response in adults to better understand how a viral infection might lead to loss of immune tolerance and rheumatoid arthritis.

Methods: Clinical data and sera were obtained from adults five weeks post-COVID-19 (positive SARS-CoV-2 test in the spring of 2020) or the following subjects with no past COVID-19: rheumatoid arthritis, Sjögren’s disease, lupus, smokers, and age- and sex-matched controls. Sera were used in a high density peptide array to evaluate IgA, IgM, and IgG binding to all possible 16 amino acid peptides derived from human IgG1-4 and the proteomes and proteins of several viruses including SARS-CoV-2 with results confirmed by ELISA. Antibodies were purified to evaluate cross-reactivity by ELISA. Data were analyzed by Kruskal-Wallis with Dunn’s multiple comparisons tests, Mann-Whitney test, Wilcoxon matched-pairs signed rank test, and MixTwice.

Results: We identified three novel IgG epitopes (IgG1-131, IgG1-238, IgG1-293) bound by antibodies in COVID-19 but not rheumatoid arthritis, Sjögren’s disease, lupus, smokers, or controls. In contrast, a hinge peptide, IgG1-104, was recognized by rheumatoid arthritis and Sjögren’s disease antibodies. A polyreactive IgM-RF bound IgG1-131, IgG1-238, and many viral peptides with a tripeptide motif, as well as IgG Fc and SARS-CoV-2 spike proteins. In contrast, a previously identified rheumatoid arthritis-specific RF that binds homocitrullinated IgG1-219 recognized IgG Fc, but not motif-containing peptides or spike.

Conclusion: RFs are not a single entity in multiple diseases, but rather have disease-specific IgG reactivity and unique polyreactivities that reflect the broader immune response. Moreover, virus-induced, motif-driven polyreactivity, as opposed to molecular mimicry among a small number of antigens, can drive autoreactivity against IgG. These findings provide new insights into how viral infection may trigger immune tolerance loss with potential implications for rheumatoid arthritis and millions of people post-COVID-19.


Disclosures: M. Amjadi: None; M. Parker: JangoBio, 3; Z. Zheng: Google, 3; A. Robbins: None; M. Denny: None; S. McCoy: Bristol-Myers Squibb(BMS), 2, Horizon, 2, Kiniksa, 2, Novartis, 2, Otsuka/Visterra, 2, Target RWE, 2; I. Ong: None; M. Shelef: None.

To cite this abstract in AMA style:

Amjadi M, Parker M, Zheng Z, Robbins A, Denny M, McCoy S, Ong I, Shelef M. Novel and Unique Rheumatoid Factors Cross-React with Viral Epitopes in COVID-19 [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/novel-and-unique-rheumatoid-factors-cross-react-with-viral-epitopes-in-covid-19/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-and-unique-rheumatoid-factors-cross-react-with-viral-epitopes-in-covid-19/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology